HRAS and glioblastoma: Microarray experiments of cancer driver gene expression in human glioblastoma cells exposed to a new tetrac-containing agent, P-bi-TAT, revealed that expression of at least nine cancer driver genes is significantly downregulated in primary human glioblastoma multiforme cells treated with P-bi-TAT, including AKT1, AKT2, CD4, ERBB2, HRAS, IDH2, KIT, MAP2K7 (MKK7; JNKK2), and MLST8 (GBL; LST8).